Five things for pharma marketers to know: Tuesday, December 11, 2018
WPP restructuring plan introduced; New Zealand legalizes medical marijuana; Gottlieb again blasts insulin makers.
News
Mark Read interview: ‘No more major agency network mergers are planned’
WPP chief executive outlines plan to be ‘creative transformation company’.
WPP to be ‘creative transformation company’ as strategy review focuses on growth
Mark Read will focus on communications, experience, commerce, and technology.
Fishawack acquires creative marketing consultancy Blue Latitude Health
Fishawack is continuing to build out its U.S. footprint with this latest acquisition.
Five things for pharma marketers to know: Monday, December 10, 2018
Gilead names Roche veteran as CEO; Investigation into generic price fixing expands; Doctors, medical journals fail to disclose conflicts of interest.
Hill-Rom partners with EarlySense to create a smarter hospital bed
The “smart bed” could spur hospitals to market their own rooms to attract patients.
Analysts: Merck’s Gardasil undervalued by billions of dollars
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Five things for pharma marketers to know: Friday, December 7, 2018
J&J unit to pay $300m-plus to settle kickback allegations; Healthcare spending growth rate slowed again in 2017; Sandoz plans generic EpiPen early next year.
Xeomin launches campaign to end stigma against anti-aging injectables
Xeomin, made by Merz, is hoping to differentiate itself in a market dominated by Allergan’s Botox.
Want to read more?
Please login or register first to view this content.
